Health system delay in treatment of multidrug resistant tuberculosis patients in Bangladesh

Abstract

BackgroundBangladesh is one of the 27 high burden countries for multidrug resistant tuberculosis listed by the World Health Organization. Delay in multidrug resistant tuberculosis treatment may allow progression of the disease and affect the attempts to curb transmission of drug resistant tuberculosis. The main objective of this study was to investigate the health system delay in multidrug resistant tuberculosis treatment in Bangladesh and to explore the factors related to the delay.MethodsInformation related to the delay was collected as part of a previously conducted case–control study. The current study restricts analysis to patients with multidrug resistant tuberculosis who were diagnosed using rapid diagnostic methods (Xpert MTB/RIF or the line probe assay). Information was collected by face-to-face interviews and through record reviews from all three Government hospitals providing multidrug resistant tuberculosis services, from September 2012 to April 2013. Multivariable regression analysis was performed using Bootstrap variance estimators. Definitions were as follows: Provider delay: time between visiting a provider for first consultation on MDR-TB related symptom to visiting a designated diagnostic centre for testing; Diagnostic delay: time from date of diagnostic sample provided to date of result; Treatment initiation delay: time between the date of diagnosis and date of treatment initiation; Health system delay: time between visiting a provider to start of treatment. Health system delay was derived by adding provider delay, diagnostic delay and treatment initiation delay.ResultsThe 207 multidrug resistant tuberculosis patients experienced a health system delay of median 7.1 weeks. The health system delay consists of provider delay (median 4 weeks), diagnostic delay (median 5 days) and treatment initiation delay (median 10 days). Health system delay (Coefficient: 37.7; 95 %; CI 15.0–60.4; p 0.003) was associated with the visit to private practitioners for first consultation.ConclusionsDiagnosis time for multidrug resistant tuberculosis was fast using the rapid tests. However, some degree of delay was present in treatment initiation, after diagnosis. The most effective way to reduce health system delay would be through strategies such as engaging private practitioners in multidrug resistant tuberculosis control.

Gridlock from Diagnosis to Treatment of Multidrug Resistant Tuberculosis (MDR-TB) in Tanzania: Patients’ Perspectives from the Focus Group Discussion

“…Frontline HCW routinely failed to suspect and test for MDR-TB suggesting that educational initiatives directed at HCW may have considerable programmatic benefit. Yet diagnostic delay was common even in centers that provided TB services, contrary to other countries where patients who attended TB centers had an advantage of being suspected and screened early [12]. Likely more important is that the health system lacks efficient mechanisms for onsite specimen testing or referral of specimens and relaying of results, a common phenomenon occuring in many developing countries [13], but one in which if ameliorated would concurrently raise awareness and testing for MDR-TB among the HCW.…”

FAST implementation in Bangladesh: high frequency of unsuspected tuberculosis justifies challenges of scale-up

“…Although the Bangladesh National TB Control Programme (NTP) covers 99% of the population and provides free services including TB medications, significant delays in care-seeking, treatment initiation and completion for drug-sensitive and drug-resistant TB remain 2,3 , despite the roll out of rapid molecular diagnostics such as Xpert® MTB/RIF (Cepheid, Sunnyvale, CA) 4,5 .…”

Diagnosis and treatment of TB patients with rifampicin resistance detected using Xpert® MTB/RIF in Zimbabwe

“…26 Possible reasons for delays in starting treatment in Zimbabwe might be the time taken in conducting the baseline biochemistry tests on liver and renal function and the decision to start MDR-TB treatment, which is made by the clinical management team. Previous studies conducted elsewhere have shown that delayed treatment is due to a combination of patient and health system factors, [27][28][29] and these need to be addressed.…”